李氏大藥廠(00950.HK)聯營與SERI訂立策略夥伴關係諒解備忘錄
格隆匯2月2日丨李氏大藥廠(00950.HK)公佈,於2021年1月15日,集團聯營公司兆科(香港)眼科藥物有限公司與Singapore Eye Research Institute Pte Ltd(下稱SERI)訂立一份諒解備忘錄,以於眼科研究及開發領域建立策略夥伴關係。
按照諒解備忘錄,兆科眼科香港及SERI將於框架內物色合作機會,包括但不限於:臨牀前研究;臨牀試驗;向兆科眼科香港授出SERI資產及技術的使用許可;及科學交流及知識分享。
據悉,SERI為新加坡在眼科及視覺研究方面的國立研究院,由一支五人團隊於1997年創立,現已發展成一支擁有逾250名人員的團隊,當中包括臨牀科學家、科學家、研究員、哲學博士生及支援人員。SERI於新加坡亦擁有逾240個關於多個眼科部門的附屬學院、生物醫學院及專上教育中心,使之成為新加坡的最大研究院之一及亞太區的最大眼科研究院。
SERI的使命為進行影響深遠的眼科研究,防止失明、低視能以及常見於新加坡人及亞洲人的主要眼疾。SERI於過去十年已進行多個標誌性的研究項目並已取得實質成效及成功個案,令眾多患者受惠。此等項目為大幅改良眼疾治療及預防方法奠下基礎,不僅惠及新加坡人或亞洲人,全球患者亦得享成果。
預期諒解備忘錄所擬定進行的合作若然落實,將為兆科眼科香港及SERI雙方帶來長遠策略價值。擬與SERI建立的策略夥伴關係亦將加強兆科眼科香港在研發方面的創新實力,為亞洲區內有需要的患者提供更多創新治療方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.